Latest Gilead Sciences News & Updates

See the latest news and media coverage for Gilead. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gilead Sciences (Gilead)

Biopharmaceutical company focused on virology, oncology and inflammation

Last updated Today

Latest news about Gilead Sciences (Gilead)

In short: Gilead expanded its oncology and HIV portfolios with key FDA approvals, strategic acquisitions, and positive clinical trial results.

July 24 Gilead

The positive opinion based on Phase 3 ASCENT-04 study showed 35% reduced risk of progression or death in PD-L1 positive patients.

July 21 Gilead

The ISL/LEN regimen maintained virological suppression and was noninferior to daily therapy at Week 48.

July 10 Gilead

The approval is for first-line metastatic triple-negative breast cancer, with coverage on patient impact.

June 24 Gilead

Approval based on ASCENT-03 and ASCENT-04 trials showing significant progression-free survival benefit.

July 31 Business Insider

Trials show lenacapavir can all but eliminate the risk of HIV infection. Yet in the countries where it was tested, most people can't afford it.

July 28 Yahoo Finance

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings...

July 27 Seeking Alpha

ViiV says two-drug Dovato matches Gilead’s Biktarvy in HIV suppression in a phase 3b study. Read mor...

July 27 Pharmaceutical Executive

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line tre...

Never miss news about Gilead

Track Gilead and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Gilead and other trending companies.